Dynavax to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021

EMERYVILLE, Calif., April 22, 2021 /PRNewswire/ -- Dynavax Technologies Corporation DVAX, a biopharmaceutical company focused on developing and commercializing novel vaccines, will report first quarter 2021 financial results on Thursday, May 6, 2021, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Thursday, May 6, 2021 at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.  Alternatively, participants may dial (866) 420-4066 (domestic) or (409) 217-8237 (international) and refer to conference ID 4533398.  A replay of the webcast will be available for 30 days following the live event.

About Dynavax

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:

Nicole Arndt, Senior Manager, Investor Relations

narndt@dynavax.com 

510-665-7264

Derek Cole, President

Investor Relations Advisory Solutions

derek.cole@IRadvisory.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-report-first-quarter-2021-financial-results-and-host-conference-call-on-may-6-2021-301275359.html

SOURCE Dynavax Technologies